Abstract: Featured is a method for assessing risk of a patient condition. Such a method includes providing criteria that relate predetermined parameters to each other, inputting observations into given criterion and relating observations of one or more acquired parameters, and converging the given criterion so as to provide an output representative of a patient condition. Such a method further includes translating the output into a visual form such as displaying the output on a display device.

Abstract: Featured is a method for assessing risk of a patient condition. Such a method includes providing criteria that relate predetermined parameters to each other, inputting observations into given criterion and relating observations of one or more acquired parameters, and converging the given criterion so as to provide an output representative of a patient condition. Such a method further includes translating the output into a visual form such as displaying the output on a display device.

Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.

Abstract: The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.

Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.

Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.

Abstract: A process of treating trauma induced factor V consumptive coagulopathy is presented whereby a subject is administered a preparation of isolated factor V or a variant thereof. Administration of factor V surprisingly improves clot times and reduces the severity and propensity of bleeding events.

Abstract: The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.

Abstract: Featured are methods for assessing hemostatic risk including the risk for ACS. Such methods include acquiring blood/plasma composition based on a biological sample obtained from a subject, determining parameters associated with blood clotting, simulating in silico blood clotting using the determined parameters and comparing the results of such simulation to a reference and to determine the hemostatic risk from said comparing. In further embodiments, such methods further include selecting a treatment regime or protocol based on the results of such comparing. In yet further embodiments, such methods further include assessing the efficacy of medicants, drugs and the like of a given treatment protocol such as by simulating in silico the application of such medicants, drugs and the like.

Abstract: Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.

Abstract: Disclosed are compositions of bone precursor cells and methods for their preparation and use. Bone precursor cells are cells which are not hematopoietic and which can differentiate into osteoblasts upon exposure to a bone growth factor and deposit calcium into the extracellular matrix. Such bone precursor cells are useful in the treatment of certain bone related disorders and diseases, such as osteoporosis, or in promoting fracture repair. In addition, methods of differentiating bone precursor cells into osteoblasts, and other diagnostic and even prognostic methods are provided.

Abstract: The instant invention describes a method for establishing the hemostatic competence of blood, wherein the steps of the method include obtaining a blood sample from a subject, contacting the blood sample with an effective amount of tissue factor under conditions conducive to coagulating blood; and detecting the amount of thrombin in the blood sample at a pre-determined time point. The invention also describes a method for testing the capacity of an individual subject to produce thrombin, wherein the steps of the method include obtaining a blood sample from the subject; contacting the blood sample with an effective amount of tissue factor under conditions conducive to coagulating blood; and detecting the amount of thrombin produced in the blood sample at a pre-determined time point.

Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307–356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 ?M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.

Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.

Abstract: Disclosed are compositions of bone precursor cells and methods for their preparation and use. Bone precursor cells are cells which are not hematopoietic and which can differentiate into osteoblasts upon exposure to a bone growth factor and deposit calcium into the extracellular matrix. Such bone precursor cells are useful in the treatment of certain bone related disorders and diseases, such as osteoporosis, or in promoting fracture repair. In addition, methods of differentiating bone precursor cells into osteoblasts, and other diagnostic and even prognostic methods are provided.

Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307-356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 &mgr;M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.

Abstract: Disclosed are compositions of bone precursor cells and methods for their preparation and use. Bone precursor cells are cells which are not hematopoietic and which can differentiate into osteoblasts upon exposure to a bone growth factor and deposit calcium into the extracellular matrix. Such bone precursor cells are useful in the treatment of certain bone related disorders and diseases, such as osteoporosis, or in promoting fracture repair. In addition, methods of differentiating bone precursor cells into osteoblasts, and other diagnostic and even prognostic methods are provided.

Abstract: Peptides derived from amino acids 307 to 356 of the human blood coagulation factor Va are provided. Such peptides comprise: i) a length of between 3 and 50 amino acids, ii) a minimum of 3 contiguous amino acids from the 307-356 heavy chain region of factor Va, excluding peptide segments comprising amino acids 311 to 325 and amino acids 321 to 335, iii) optional additional amino acids at one or both ends of the contiguous amino acids such that the entire peptide is at least 60% identical to a sequence within 307 to 356 of factor Va, and iv) have an IC50 of between 50 nM to 500 &mgr;M for inhibition of prothrombinase. The present invention also provides a pharmaceutical composition comprising one or more prothrombinase-inhibiting peptide segments. The present invention also provides administration of the pharmaceutical composition to human subjects for the purpose of preventing thrombotic disorders.

Abstract: Compounds of the following formula are disclosed, wherein R1 is a peptide and R2 is an amino acid or peptide as disclosed herein: The compounds are inhibitors of activated protein C.

Abstract: The present invention provides methods for inhibiting blood clotting. In general, the methods include adding corn trypsin inhibitor (CTI) to blood or a blood product in an amount sufficient to inhibit the clotting. The CTI can be used alone or in combination with other anti-coagulants. In one aspect, the invention features plasma clotting assays featuring substantially prolonged clotting times. Clotting assays using whole or minimally altered blood are also provided. Further provided are methods for storing blood or blood products at low temperature with the CTI.